top-left-banner

Monday, Nov 24th

Last update04:02:00 PM GMT

TwitterLinkedinYoutubeGoogleFeed

Banner

User1

User2c

User3

You are here: News BioMedTech

Endomagnetics raises £2m for US trial and cancer marker launch

Endomagnetics CEO Dr Eric MayesEndomagnetics, the Cambridge UK cancer healthcare company, has raised an extra £2m to support a pivotal US clinical trial and the launch of a new cancer marker product in 2015.

Horizon clinches $750k deal with Top 10 pharma giant

Dr Darrin Disley, Horizon Discovery Group’s CEOCambridge UK medical technology business Horizon Discovery Group has landed another major deal with a top 10 pharmaceutical company to profile a lead cancer asset.

Shanghai plans healthcare future with help from Cambridge medics

Chinese delegation of senior directors from state-owned Shanghai Hospital Development CentreA delegation of senior directors from state-owned Shanghai Hospital Development Centre (SHDC) have been in Cambridge to learn best practice in healthcare and medical technology from leading medics – knowledge that will underpin future strategy in China.

Owlstone unveils new manufacturing facility

Co-founder Billy Boyle (left) with Daniel Zeichner at the opening of Owstone’s new Science Park facilityLabour Parliamentary candidate Daniel Zeichner cut the ribbon on Owlstone's new manufacturing facility on the Cambridge Science Park.

Scientists seek funds to grow lung tissue in the lab

Michaela-and-FerdaTwo Cambridge University scientists have launched a crowdfunding campaign to help develop their vision to build lung tissue in the lab. They believe the technology using stem cells could prove significant in combating lung cancer.

Sareum secures European patent for auto immune disease technology

Sareum CEO Dr Tim MitchellCambridge cancer drug pioneer Sareum has earned a crucial first patent from the European Patent Office for inventions associated with its TYK2 kinase inhibitor programme – technology that could improve treatment of a range of auto immune diseases.

Cambridge startup hopes to find cure for US boy’s rare disease

Bertrand-MightA Cambridge UK medical technology startup which matches safe drugs to rare diseases is working on a potential cure for a six-year-old American boy who is the first patient ever to be diagnosed with NGLY-1 deficiency and loss of function.

Dead soldier’s DNA in battle against killer disease

Dr-Alison-MatherA hundred years after his death on the Western Front a British soldier is still fighting – this time to save the lives of children dying from dysentry in developing countries.

AstraZeneca in good shape for Cambridge move

Pascal-SoriotFor an entity awaiting a heart transplant – moving the heart of its corporate and R & D business to the Cambridge medical technology cluster – AstraZeneca looks in remarkably rude health.

BioSilta strengthens team and completes HQ

Bob-PenneyBioSilta Ltd, a developer of advanced, reagent-based microbial growth systems, has completed the set-up of operational and commercial headquarters in St Ives.

F-star launches oncology spin-out

John Haurum, CEO of F-starF-star, the Cambridge UK oncology-focused biopharma company, has launched an independent spin-out business – F-star Beta – which has been granted exclusive licences to a range of oncology assets.

MedImmune pays $150m for cancer-imaging technology

Dr Bahija Jallal, executive VP, MedImmuneMedImmune, AstraZeneca’s Cambridge UK-based biologics R & D arm, has agreed to buy Definiens – a German company that has pioneered a world-leading imaging and data analysis technology – in a deal worth an initial $150 million plus certain milestones.

Tech spy inside the body will diagnose cancer faster

CamCon-EndofotonicsA fibre optic probe inserted inside the body to capture the molecular fingerprint of tissue is being commercially developed by Cambridge Consultants and client – Singapore startup Endofotonics – to help doctors make real-time diagnoses of stomach and bowel cancer.

Wall Street giant could take F-star for up to $475m

F-star CEO John HaurumBristol-Myers Squibb, the Wall Street-quoted pharmaceutical heavyweight, has hammered out an exclusive option to buy Cambridge UK biotech F-star Alpha in a deal that could stack up to $475 million.

TGAC nurtures the genomics generation

TGAC opens its doors for a new venture – ‘Children of TGACThe Genome Analysis Centre (TGAC) in Norwich UK is nurturing a young generation of potential scientists.

Cambridge tech at heart of £53m dementia research platform

Cambridge Cognition CEO Nick KertonCutting edge technology from Cambridge Cognition and other Cambridge enterprises is playing a significant role in The Medical Research Council’s £53 million Dementias Research Platform UK (DPUK).

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »

Page 1 of 66